Exclusive: Royalty Pharma considers sweetened deal for Elan - sources
NEW YORK (Reuters) - Investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug Tysabri hits certain sales milestones, two people familiar with the matter said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Low Body Weight Linked to PML Risk With Natalizumab in MS Low Body Weight Linked to PML Risk With Natalizumab in MS
Results of a new study suggest that low body mass may be a risk factor for progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
PML and body weight
Analysis presented at last month's AAN (American Academy of Neurology) meeting found that PML (progressive multifocal leukoencephalopathy), a side effect of Tysabri, was more prevalent in people with lower body weight. Whether weight is the risk factor or just indicative of something else is not clear.
Medscape (requires free registration)
PML (Progressive multifocal leukoencephalopathy) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 2, 2013 Category: Neurology Source Type: news
MS brain bank
The role of the MS brain bank at Imperial College in the development of Tysabri and other potential treatments for MS.
Imperial College
Organ donations - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 19, 2013 Category: Neurology Source Type: news
Early Detection of PML With Natalizumab Improves OutcomeEarly Detection of PML With Natalizumab Improves Outcome
Detecting natalizumab-associated PML infection before symptoms arise may improve survival and reduce disability, new retrospective data suggest. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Improved Survival for MS-Related Brain Infection
(Ivanhoe Newswire) -- A drug called natalizumab is used to effectively treat multiple sclerosis (MS), but it also increases the risk of a rare potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). New research out of Biogen Idec in Weston, MA, suggests that early detection of PML may improve survival rates and disability levels. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - March 12, 2013 Category: Consumer Health News Source Type: news
Early detection of MS treatment complication may improve survival
(American Academy of Neurology) The drug natalizumab is effective for treating multiple sclerosis, but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, Mar. 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 10, 2013 Category: Global & Universal Source Type: news
Natalizumab May Be Useful for Pediatric MSNatalizumab May Be Useful for Pediatric MS
A new study suggests natalizumab may safely be used to good effect in children with multiple sclerosis who have breakthrough disease activity despite first-line therapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Royalty Pharma Makes Offer for Elan
Pharmaceutical investor Royalty Pharma said it made a takeover offer to Elan, two days before the Irish drug maker outlined its investment plans after the sale of its stake in multiple sclerosis drug Tysabri. (Source: WSJ.com: Health)
Source: WSJ.com: Health - February 26, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
Royalty makes bid to take over Elan
The $11-a-share move marks an effort by the buyout group to gain access to future income from Tysabri, the multiple sclerosis drug (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 25, 2013 Category: Pharmaceuticals Source Type: news
Royalty Pharma may offer $6.6 billion bid for Elan
DUBLIN (Reuters) - U.S. investment firm Royalty Pharma has made a $6.6 billion approach to Irish drugmaker Elan, targeting royalty rights for multiple sclerosis treatment Tysabri worth hundreds of millions of dollars annually. (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Royalty Pharma in $6.6bn bid for Elan
Investment group seeks to take control of Dublin-based group for access to future income from Elan’s multiple sclerosis drug Tysabri (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 25, 2013 Category: Pharmaceuticals Source Type: news
Elan Provides Update Post Restructuring Announcement of Tysabri Collaboration
Post-Closing Deployment Plan For
Upfront Payment Of $3.25 Billion
Tax Efficient Transaction Enables
Substantially All of Proceeds To Be Realized and Utilized
Deployment Of Capital To Diversify
Business and Strengthen Capital Structure
Outstanding... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2013 Category: Pharmaceuticals Source Type: news
Elan to return $1 billion to shareholders from multiple sclerosis drug sale
DUBLIN (Reuters) - Irish drugmaker Elan will return $1 billion to shareholders, giving them an immediate boost from the sale of its stake in multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Elan plans $1 billion buyback and acquisitions
DUBLIN (Reuters) - Irish drugmaker Elan will return $1 billion to shareholders and seek acquisitions with the proceeds of selling its stake in blockbuster multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
